Dr. Reddy’s Tells Delhi High Court It Won’t Sell Ozempic-like Drug in India Amid Patent Dispute

Dr. Reddy’s Laboratories informed the Delhi High Court that it will not sell its semaglutide-based drug in India, following a patent infringement suit by Novo Nordisk over its diabetes drug, Ozempic.

The pharma company, however, reserved the right to export the drug to countries where Novo Nordisk doesn’t hold a patent.

Dr. Reddy’s has a manufacturing license but hasn't received approval to sell in India. The company also challenged the validity of Novo Nordisk’s patent, alleging evergreening and lack of novelty.

The court took the undertaking on record and listed the matter for further hearing on August 19, 2025.